Advertisement

Gestational Trophoblastic Disease

  • P. K. Sekharan
Chapter

Abstract

Gestational trophoblastic disease (GTD) is a spectrum of abnormal trophoblastic hyperplasia resulting from abnormal conception; there is imbalance in the genetic input from the ovum and sperm. The genetic makeup in complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM) is different. In both types of mole, there is an excess of paternal chromosomes resulting in rapidly multiplying trophoblastic cells of both the cytotrophoblastic and the syncytiotrophoblastic layers, which is capable of producing excess of human chorionic gonadotropin (hCG) with potential to progress to gestational trophoblastic neoplasia (GTN). Gestational trophoblastic neoplasia can also develop from previously normal trophoblasts as in cases of choriocarcinoma and placental site trophoblastic tumor (PSTT) following term delivery and abortion. All types of GTN, irrespective of their genetic origin, share the feature of producing high level of hCG. Gestational trophoblastic neoplasia is one of the most chemosensitive and highly curable cancers, even in the presence of widespread metastatic disease, and in most cases with preservation of fertility. GTD is unique because the maternal lesions arise from the fetal tissue.

Keywords

Hydatidiform Mole Gestational Trophoblastic Disease Molar Pregnancy Gestational Trophoblastic Neoplasia Complete Hydatidiform Mole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: two entities. A morphological and cytogenetic study with some clinical considerations. Am J Obstet Gynecol. 1977;127:167–70.PubMedGoogle Scholar
  2. 2.
    Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol. 1978;131:665–71.PubMedGoogle Scholar
  3. 3.
    Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evolution of the complete and partial mole. Am J Obstet Gynecol. 1978;132:20–7.PubMedGoogle Scholar
  4. 4.
    Surti U, Szulman AE, O'Brien S. Dispermic origin and clinical outcome of three complete hydatidiform moles with 46, XY karyotype. Am J Obstet Gynecol. 1982;144:84–7.PubMedGoogle Scholar
  5. 5.
    Lawler SD, Pickthall VJ, Fisher RA, Povey S, Evans MW, Szulman AE. Genetic studies of complete and partial hydatidiform moles. Lancet. 1979;2:58.Google Scholar
  6. 6.
    Azuma C, Saji F, Tokugawa Y, Kimura T, Nobunaga T, Takemura M, Kameda T, Tanizawa O. Application of gene amplification by polymerase chain reaction to genetic analysis of molar mitochondrial DNA: the detection of anuclear empty ovum as the cause of complete mole. Gynecol Oncol. 1991;40:29–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Wake N, Fujino T, Hoshi S, et al. The propensity to malignancy of dispermic heterozygous moles. Placenta. 1987;8:319–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Moglabey YB, Kircheisen R, Seoud M, El Mogharbel N, Van den Veyver I, Slim R. Genetic mapping of a maternal locus responsible for familial hydatidiform moles. Hum Mol Genet. 1999;8:667–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Murdoch S, Djuric U, Mazhar B, et al. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat Genet. 2006;38:300–2.CrossRefPubMedGoogle Scholar
  10. 10.
    Deveault C, Qian JH, Chebaro W, et al. NLRP7 mutations in women with diploid androgenetic and triploid moles: a proposed mechanism for mole formation. Hum Mol Genet. 2009;18:888–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Sebire NJ, Foskett M, Fisher RA, Rees H, Newlands E, Seckl M. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG. 2002;109:99–102.CrossRefPubMedGoogle Scholar
  12. 12.
    Fisher RA, Newlands ES, et al. Diploid hydatidiform moles with foetal blood cells in molar villi. 2—genetics. J Pathol. 1997;181(2):189–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Seckl MJ, Fishjer RA, Newlands ES, et al. Choriocarcinoma and partial hydatidiform mole. Lancet. 2000;356:36–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Szulman AE, Surti U, Berman M. Patient with partial mole requiring chemotherapy. Lancet. 1978;ii:1099.CrossRefGoogle Scholar
  15. 15.
    Loi LM, Sivanesaratnam V. Malignant evolution with fatal outcome in a patient with partial hydatidiform mole. Aust N Z J Obstet Gynaecol. 1981;21:51–2.CrossRefGoogle Scholar
  16. 16.
    Szulman AE, Wong LC, Hsu C. Residual trophoblastic disease in association with partial hydatidiform mole. Obstet Gynecol. 1981;57:392–4.PubMedGoogle Scholar
  17. 17.
    Acosta-Sison H. Ab initio choriocarcinoma: two unusual cases. Obstet Gynecol. 1959;13:350–2.PubMedGoogle Scholar
  18. 18.
    Scully R, Young R. Trophoblastic pseudotumour: a reappraisal. Am J Surg Pathol. 1981;5:75–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Vardar MA, Altintas A. Placental-site trophoblastic tumor. Principles of diagnosis, clinical behaviour and treatment. Eur J Gynaecol Oncol. 1995;16(4):290.PubMedGoogle Scholar
  20. 20.
    Eckstein RP, Paradinas FJ, Bagshawe KD. Placental site trophoblastic tumour (trophoblastic pseudotumour): a study of four cases requiring hysterectomy including one fatal case. Histopathology. 1982;6:211–26.CrossRefPubMedGoogle Scholar
  21. 21.
    Fisher RA, Paradinas FJ, Newlands ES, Boxer GM. Genetic evidence that placental site trophoblastic tumours can originate from a hydatidiform mole or a normal conceptus. Br J Cancer. 1992;65:355–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bower M, Paradinas FJ, Fisher RA, et al. Placental site tropho- blastic tumour: molecular analysis and clinical experience. Clin Cancer Res. 1996;2:897–902.Google Scholar
  23. 23.
    Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol. 1998;22(11):1393.CrossRefPubMedGoogle Scholar
  24. 24.
    Palmer JE, Macdonald M, Wells M, Hancock BW, Tidy JA. Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med. 2008;53(7):465.PubMedGoogle Scholar
  25. 25.
    Benson CB, Genest DR, Bernstein MR, Soto-Wright V, Berkowitz RS. Sonographic appearance of first trimester complete hydatidiform moles. Ultrasound Obstet Gynecol. 2000;16:188–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Fisher RA, Hodges MD, Rees HC, et al. The maternally transcribed gene p57(KIP2) (CDNK1C) is abnormally expressed in both androgenetic and biparental complete hydatidiform moles. Hum Mol Genet. 2002;11:3267–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Bahar AM, et al. Hydatidiform in the elderly: hysterectomy or evacuation. Int J Obstet Gynecol. 1989;29:233.CrossRefGoogle Scholar
  28. 28.
    Kohorn EI. hydatidiform mole and gestational Trophoblastic disease in Southern Connecticut. Obstet Gynecol. 1982;59:78–84.PubMedGoogle Scholar
  29. 29.
    Kim O, Moon I, Kim KT, et al. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol. 1986;67(5):690–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Berkowitz RS, Goldstien DP, et al. Oral contraceptives and postmolar trophoblastic disease. Obstet Gynecol. 1981;58:474.PubMedGoogle Scholar
  31. 31.
    Bagshawe KD. Trophoblastic neoplasia. In: Holland Frei III JF, Bast Jr R, et al., editors. Cancer medicine. 3rd ed. Baltimore: Williams & Wilkins; 1993. p. 169–968.Google Scholar
  32. 32.
    Lurain JR, Brewer JI, Torok FE, Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol. 1983;145:591–5.PubMedGoogle Scholar
  33. 33.
    Morrow CP, Kletzky OA, DiSaia PT, et al. Clinical and laboratory correlates of molar pregnancy and trophoblastic disease. Am J Obstet Gynecol. 1977;128:424–30.PubMedGoogle Scholar
  34. 34.
    Sekharan PK, Sreedevi NS, Rasheedabeegam O, Radhadevi VP, Jayandhiraghavan T, Guhan B. Management of postmolar gestational trophoblastic diseases with methotrexate and folinic acid: 15 years of experience. J Reprod Med. 2006;51:835–40.PubMedGoogle Scholar
  35. 35.
    Kohorn EI, Goldstein DP, Hancock BW, et al. Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society. Int J Gynecol Cancer. 2000;10:84–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Ngan HY. The FIGO staging for gestational trophoblastic neoplasia 2000, FIGO Committee Report. Int J Gynecol Obstet. 2002;77:285–7.CrossRefGoogle Scholar
  37. 37.
    Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976;38:1373–85.CrossRefPubMedGoogle Scholar
  38. 38.
    WHO. Scientific Group: gestational trophoblastic diseases technical report series no. 692. Geneva; 1983.Google Scholar
  39. 39.
    Bagshawe KD, Newlands ES, et al. The role of low dose Methotrexate and Folinic acid in gestational trophoblastic tumours. Br J Obstet Gynecol. 1989;96:795.CrossRefGoogle Scholar
  40. 40.
    Berkowitz RS, Goldstein DP, Bernstein MR. Ten years experience with methotrexate and Folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol. 1986;23(1):111–8.CrossRefPubMedGoogle Scholar
  41. 41.
    McNeish IA, Strickland S, Holden L, et al. Low risk persistent gestational trophoblastic disease: outcome following initial treatment with low-dose methotrexate and folinic acid, 1992–2000. J Clin Oncol. 2002;20:1838–44.CrossRefPubMedGoogle Scholar
  42. 42.
    Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. 2010. www.thelancet.com. Published online July 28, 2010. doi: 10.1016/S0140-6736(10)60280-2.
  43. 43.
    Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple therapy in the management of high-risk metastatic gestational trophoblastic tumours. Gynecol Oncol. 1984;19(2):173–81.CrossRefPubMedGoogle Scholar
  44. 44.
    Lurain JR, Brewer JI. Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D and cyclophosphamide chemotherapy. Obstet Gynecol. 1985;65:8304.Google Scholar
  45. 45.
    Bagshawe KD, Begent RHJ. The management of high-risk choriocarcinoma. Semin Oncol. 1982;9:198–203.PubMedGoogle Scholar
  46. 46.
    Newlands ES, Bagshawe KD, Begent RHJ, et al. Results with EMA-CO REGIMEN in high-risk gestational trophoblastic tumors. Br J Obstet Gynecol. 1991;98:550–7.CrossRefGoogle Scholar
  47. 47.
    Vejerslev LO. Clinical management and diagnostic possibilities in hydatidiform mole with co-existent fetus. Obstet Gynecol Surv. 1991;46:577–88.CrossRefPubMedGoogle Scholar
  48. 48.
    Newlands ES. Opinion: twin gestation comprising mole in concert with normal foetus: test, treat, abort or let go to term. J Int Soc Troph Dis. 1999;3:3–5.Google Scholar
  49. 49.
    Goldstien DP, Berkowitz RS. Malignant potential of Twin with one mole and one normal fetus. J Int Soc Troph Dis. 1999;3:5–7.Google Scholar
  50. 50.
    Steller MA, Genest DR, Bernstein MR. Clinical features of multiple conception with partial or complete molar pregnancy and coexisting foetus. J Reprod Med. 1994;39:147–54.PubMedGoogle Scholar
  51. 51.
    Cole LA. Choosing a test for monitoring gestational trophoblastic disease. In: Proceedings of the XIII World congress on gestational trophoblastic disease, Hongkong. Abstract # 10.3; 2005.Google Scholar
  52. 52.
    Cole LA. Choosing a test for monitoring gestational trophoblastic disease. In: Proceedings of the XIII World congress on gestational trophoblastic disease, Hongkong. Abstract # 12.4; 2005.Google Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyMedical CollegeCalicutIndia

Personalised recommendations